Recombinant Technology
Characteristics of Bloomcolla™ COL3-MD 1012
Patented product: selective, proprietary amino acid sequences and manufacturing process (China Invention Patent No. ZL202210739807.1; PCT patent application filed).
High safety: non-immunogenic, no risk of viral infection, and low endotoxin levels.
High safety: non-immunogenic, no risk of viral infection, and low endotoxin levels.
Excellent biocompatibility: 100% amino acid sequence homology with human type III collagen. High purity (>95%)and outstanding batch-to-batch consistency.
High efficacy: excellent ability to promote cell proliferation, migration, and adhesion, among other functions.
High efficacy: excellent ability to promote cell proliferation, migration, and adhesion, among other functions.
Type III collagen decreases with age.
- Total collagen levels decrease with age.
- The amount of type III collagen decreases faster than type I collagen after birth.
- The ratio of type III collagen to type I collagen gradually declines.
Recombinant Collagen Technology
- Target gene: human collagen DNA
- Vector: plasmid
- Host cells: yeast cells, E. coli, etc.
Insertion of the target gene into the vector
Introduction of DNA into the host cell
Dividing cell containing recombinant DNA
Dividing cell containing recombinant DNA
Modified gene expression
E. coli, etc.
Recombinant Collagen
Fermentation, etc.
Purification
Protein expressed by the gene
Yeast cell, etc.
Host Cell
Inserted DNA
DNA Vector
Target Gene
Target Gene
Vector
Exogenous DNA
The penetration rate of recombinant collagen used for skin rejuvenation is expected to increase from 4.8% in 2022 to 9.7% by 2027
The skin rejuvenation market based on recombinant collagen is growing rapidly
Recombinant collagen penetration rate
Collagen
Hyaluronic acid
Other
Botulinum toxin
Billion yuan
© All rights reserved. Beraderm.
Beraderm LLC
Primary State Registration Number (OGRN): 1257700208501
Russia, 115280, Moscow,
19 Leninskaya Sloboda St., Premises 62/1
19 Leninskaya Sloboda St., Premises 62/1
